

DAFTAR PUSTAKA

1. Zhang M, Cheng YJ, Sara JD, Liu LJ, Liu LP, Zhao X, et al. Circulating MicroRNA-145 is associated with acute myocardial infarction and heart failure. *Chinese medical journal*. 2017;130(1):51.
2. Ibanez B, James S, Agewall S, Antunes MJ, Ducci CB, Bueno H, et al. ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST segment elevation. *European Heart Journal*. 2017:1-66.
3. RISKESDAS. Badan Penelitian dan Pengembangan Kesehatan. Riset Kesehatan Dasar (RISKESDAS). L nas. 2013:1-384.
4. Dong YM, Liu XX, Wei GQ, Da YN, Cha L, Ma CS. Prediction of long-term outcome after acute myocardial infarction using circulating miR-145. *Scandinavian journal of clinical and laboratory investigation*. 2015;75(1):85-91.
5. Xu H, Cao H, Zhu G, Liu S, Li H. Overexpression of microRNA-145 protects against rat myocardial infarction through targeting PDCD4. *American Journal of Translational Research*. 2017;9(11):5003.
6. Tapuria N, Kumar Y, Habib MM, Amara MA, Seifalian AM, Davidson BR. Remote ischemic preconditioning: a novel protective method from ischemia reperfusion injury—a review. *Journal of Surgical Research*. 2008;150(2):304-30.
7. Cao B, Wang H, Zhang C, Xia M, Yang X. Remote ischemic Postconditioning (RIPC) of the upper arm results in protection from cardiac ischemia-reperfusion injury following primary percutaneous coronary intervention (PCI) for acute ST-segment elevation myocardial infarction (STEMI). *Medical science monitor: international medical journal of experimental and clinical research*. 2018;24:1017.
8. Kohns M, Huhn R, Bauer I, Brandenburger T. miRNA-Mediated Mechanisms of Cardiac Protection in Ischemic and Remote Ischemic Preconditioning-A Qualitative Systematic Review. *Shock*. 2019;51(1):44-51.
9. Yan L, Guo N, Cao Y, Zeng S, Wang J, Lv F, et al. miRNA-145 inhibits myocardial infarction-induced apoptosis through autophagy via Akt3/mTOR signaling pathway in vitro and in vivo. *International journal of molecular medicine*. 2018;42(3):1537-47.
10. Navickas R, Gal D, Laucevičius A, Tapauskaitė A, Zdanytė M, Holvoet P. Identifying circulating microRNAs as biomarkers of cardiovascular disease: a systematic review. *Cardiovascular research*. 2016;111(4):322-37.
11. Meder B, Keller A, Vogel B, Haas J, Sedaghat-Hamedani F, Kayvanpour E, et al. MicroRNA signatures in total peripheral blood as novel biomarkers for acute myocardial infarction. *Basic research in cardiology*. 2011;106(1):13-23.
12. Wang C, Jing Q. Non-coding RNAs as biomarkers for acute myocardial infarction. *Acta Pharmacologica Sinica*. 2018;39(7):1110-9.
13. Gao H, Guddeti RR, Matsuzawa Y, Liu LP, Su LX, Guo D, et al. Plasma levels of microRNA-145 are associated with severity of coronary artery disease. *PloS one*. 2015;10(5):e0123477.
14. Higashi K, Yamada Y, Minatoguchi S, Baba S, Iwasa M, Kanamori H, et al. MicroRNA-145 repairs infarcted myocardium by accelerating cardiomyocyte autophagy. *American Journal of Physiology-Heart and Circulatory Physiology*. 2015;309(11):H1813-26.
15. Dharma, S. Infark miokard akut disertai elevasi segmen ST: Patologi, patofisiologi dan gambaran klinis. In: Yuniadi, Y, Hermanto, DY, Siswanto, BB. *Buku Ajar Kardiovaskular Jilid 2*. Jakarta: Sagung Seto ; 2017: 153-9.

16. Topol, EJ, Werf, FJV. Acute myocardial infarction: early diagnosis and management. In: Topol, EJ. Textbook of Cardiovascular Medicine. 3rd edition. Philadelphia: Lippincott Williams and Wilkins; 2007: p280-1.
17. Scirica, BM, Morrow, DA. ST-elevation myocardial infarction: pathology, pathophysiology, and clinical features. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. Tenth edition. Philadelphia: Elsevier; 2015: 1072-88.
18. O'gara PT, Kuster FG, Ascheim DD, Carey DE, Chung MK, de Lemos JA, et al. 2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction: A Report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. *Circulation*. 2013;127:e362-e425.
19. Hass EE, Yang EH, Gersh BJ, O'Rourke RA. ST-segment elevation myocardial infarction. In: Hurst's The Heart Volume Two. 13th edition. United States: McGraw-Hill; 2011: 1361-64.
20. Tobing, D. Tatalaksana infark miokard elevasi segmen ST. In: Yuniadi, Y, Hermanto, DY, Siswanto, BB. Buku Ajar Kardiovaskular Jilid 2. Jakarta: Sagung Seto; 2017: 166-70.
21. Gross GJ, Auchampach JA. Reperfusion injury: does it exist?. *Journal of molecular and cellular cardiology*. 2007;42(1):12-8.
22. Kalogeris T, Baines CP, Krenz M, Korthuis RJ. Cell biology of ischemia/reperfusion injury. *International review of cell and molecular biology*. 2012;298:229-317.
23. Rangrez AY, Massy ZA, Metzinger-Le Meuth V, Metzinger L. miR-143 and miR-145: molecular keys to switch the phenotype of vascular smooth muscle cells. *Circulation: Cardiovascular Genetics*. 2011;4(2):197-205.
24. Ye D, Shen Z, Zhou S. Function of microRNA-145 and mechanisms underlying its role in malignant tumor diagnosis and treatment. *Cancer management and research*. 2019;11: 969.
25. Long X, Miano JM. Transforming growth factor- β 1 (TGF- β 1) utilizes distinct pathways for the transcriptional activation of microRNA 143/145 in human coronary artery smooth muscle cells. *Journal of Biological Chemistry*. 2011;286(34): 30119-29.
26. Li R, Yan G, Li Q, Sun H, Hu Y, Sun J, et al. MicroRNA-145 protects cardiomyocytes against hydrogen peroxide (H₂O₂)-induced apoptosis through targeting the mitochondria apoptotic pathway. *Plos One*. 2012;7(9):e44907.
27. Cannon CP, Lee TH. Approach to the patient with chest pain. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. Tenth edition. Philadelphia: Elsevier; 2015: 1197.
28. Kaur S, Jaggi AS, Singh N. Molecular aspects of ischaemic postconditioning. *Fundamental & clinical pharmacology*. 2009;23(5):521-36.
29. Vinten-Johansen J, Zhao ZQ, Jiang R, Zatta AJ. Myocardial protection in reperfusion with postconditioning. *Expert review of cardiovascular therapy*. 2005;3(6):1035-45.
30. Rossello X, Yellon DM. The RISK pathway and beyond. *Basic research in cardiology*. 2018;113(1):2.
31. Yang XM, Proctor JB, Cui L, Krieg T, Downey JM, Cohen MV. Multiple, brief coronary occlusions during early reperfusion protect rabbit hearts by targeting cell signaling pathways. *Journal of the American College of Cardiology*. 2004;44(5):1103-10.
32. Tsang A, Hausenloy DJ, Yellon DM. Myocardial postconditioning: reperfusion injury revisited. *Am J Physiol heart Circ Physiol*. 2005;289:H2-H7.
33. Tsang A, Hausenloy DJ, Mocanu MM, Yellon DM. Postconditioning: a form of "modified reperfusion" protects the myocardium by activating the phosphatidylinositol 3-kinase-Akt pathway. *Circulation research*. 2004;95(3):230-2.

34. Crimi G, Pica S, Raineri C, Bramucci E, De Ferrari GM, Klersy C, et al. Remote ischemic post-conditioning of the lower limb during primary percutaneous coronary intervention safely reduces enzymatic infarct size in anterior myocardial infarction: a randomized controlled trial. *JACC: Cardiovascular Interventions*. 2013;6(10):1055-63.
35. White SK, Frohlich GM, Sado DM, Maestrini V, Fontana M, Treibel TA, et al. Remote ischemic conditioning reduces myocardial infarct size and edema in patients with ST-segment elevation myocardial infarction. *JACC: Cardiovascular Interventions*. 2015;8:178-88.
36. Hausenloy DJ, Yellon DM. Cardioprotective growth factors. *Cardiovascular research*. 2009;83: 179-94.
37. Hoes AW, Ireland MC, Corra U, Uk CD, Ireland IG, Stephen M, et al. 2016 European Guidelines on cardiovascular disease prevention in clinical practice The Sixth Joint Task Force of the European Society of Cardiology. *Europace*. 2016;37:2315–81.
38. Kang MJ, Oh Y, Lee JC, Kim DG, Park MJ, Lee MG, et al. Lung Matrix Metalloproteinase-9 Correlates with Cigarette Smoking and Obstruction of Airflow. *Korean Med Sci*. 2003;12:821–27.
39. Bonaca MP, Creager MA. Peripheral artery disease. In: Braunwald's Heart Disease. A Textbook of Cardiovascular Medicine. Tenth edition. Philadelphia: Elsevier; 2015: 1328.
40. Soelistijo SA, Novida H, Rudijanto A, Suastika K, Manaf A. Definisi, pathogenesis, klasifikasi diabetes mellitus. In: Soelistijo SA, Novida H, Rudijanto A, Suastika K, Manaf A. *Konsensus pengelolaan dan pencegahan diabetes mellitus tipe 2 di Indonesia 2015*. Jakarta: PB. PERKENI; 2015: 6-11.
41. De Lemos JA, O'Rourke RA, Harrington RA. Unstable angina and non-ST segment elevation myocardial infarction. In: Hurst's The Heart Volume Two. 13th edition. United States: McGraw-Hill; 2011: 1333.
42. Jousilahti P, Vartiainen E, Tuomilehto J, Puska P. Sex, Age, Cardiovascular Risk Factors, and Coronary Heart Disease A Prospective Follow-Up Study of 14 786 Middle-Aged Men and Women in Finland. *Circulation*. 1999;99:1165-72.
43. Grady D, Rubin SM, Petitti DB, Fox CS, Black D, Ettinger B, et al. Hormone therapy to prevent disease and prolong life in post menopausal women. *Ann Intern Med*. 1992;117:1016–37.
44. Shahar E, Folsom AR, Salomaa VV, Stinson VL, McGovern PG, Shimakawa T, et al for the Atherosclerosis Risk in Communities (ARIC) Study Investigators. Relation of hormone- replacement therapy to measures of plasma fibrinolytic activity. *Circulation*. 1996;93:1970–75.
45. Matthews KA, Meilahn E, Kuller LH, Kelsey SF, Caggiula AW, Wing RR. Menopause and risk factors for coronary heart disease. *N Engl J Med*. 1989;321:641– 6.
46. Bonithon-Kopp C, Scarabin P-Y, Darne B, Malmejak A, Guize L. Menopause-related changes in lipoproteins and some other cardiovascular risk factors. *Int J Epidemiol*. 1990;19:42–8.
47. Escobar E. Hypertension and coronary heart disease. *Journal of human hypertension*. 2002;16.1: S61-3.
48. Flint AJ, Rexrode KM, Hu FB, Glynn RJ, Caspard H, Manson JE, et al. Body mass index, waist circumference, and risk of coronary heart disease: a prospective study among men and women. *Obesity research & clinical practice*. 2010;4.3: e171-81.
49. Heusch G, Botker HE, Przyklenk K, Redington A, Yellon D. Remote ischemic conditioning. *J Am Coll Cardiol*. 2015;65(2):177-95.
50. Weissler-Snir A, Gurevitz C, Assali A, Vaknin H, Bental T, Lador A, et al. Prognosis of STEMI patients with multi-vessel disease undergoing culprit-only PCI without

- significant residual ischemia on non-invasive stress testing. *Plos One*. 2015;10:e0138474.
51. Eriksen AHM, Andersen RF, Pallisgaard N, Sorensen FB, Jakobsen A, Hansen TF. MicroRNA expression profiling to identify and validate reference genes for the relative quantification of microRNA in rectal cancer. *PloS one*. 2016;11.3:5.
 52. Liu Z, Tao B, Fan S, Pu Y, Xia H, Xu L. MicroRNA-145 Protects against Myocardial Ischemia Reperfusion Injury via CaMKII-Mediated Antiapoptotic and Anti-Inflammatory Pathways. *Oxidative medicine and cellular longevity*. 2019;2019: 1-13.
 53. Wei Y, Jahantigh MZ, Neth P, Weber C, Schober A. MicroRNA-126,-145, and-155: a therapeutic triad in atherosclerosis?. *Arteriosclerosis, thrombosis, and vascular biology*.2013;33.3: 449-54.
 54. Fichtlscherer S, De Rosa S, Fox H, Schwietz T, Fischer A, Liebetrau C, et al. Circulating microRNAs in patients with coronary artery disease. *Circulation research*. 2010;107.5: 677-84.
 55. Xu M, Mo YY. The AKT-associated microRNAs. *Cellular and molecular life sciences*. 2012;69.21:3601-12.
 56. Thuny F, Lairez O, Roubille F, Mewton N, Rioufol G, Sportouch C, et al. Post-conditioning reduces infarct size and edema in patients with ST-segment elevation myocardial infarction. *Journal of the American College of Cardiology*.2012;59(24): 2175-81.
 57. Thibault H, Piot C, Staat P, Bontemps L, Sportouch C, Rioufol G, et al. Long-term benefit of postconditioning. *Circulation*.2008;117(8):1037.
 58. Lønborg J, Kelbæk H, Vejstrup N, Jørgensen E, Helqvist S, Saunamäki K, et al. Cardioprotective effects of ischemic postconditioning in patients treated with primary percutaneous coronary intervention, evaluated by magnetic resonance. *Circulation: Cardiovascular Interventions*.2010;3(1):34-41.
 59. Man C, Gong D, Zhou Y, Fan Y. Meta-analysis of remote ischemic conditioning in patients with acute myocardial infarction. *Scientific reports*.2017;7: 43529.
 60. Yellon DM, Ackbarkhan AK, Balgobin V, Bulluck H, Deelchand A, Dhuny MR, et al. Remote ischemic conditioning reduces myocardial infarct size in STEMI patients treated by thrombolysis. *Journal of the American College of Cardiology*.2015;65(25): 2764-65.
 61. Lavi S, D'Alfonso S, Diamantouros P, Camuglia A, Garg P, Teefy P, et al. Remote ischemic postconditioning during percutaneous coronary interventions: remote ischemic postconditioning-percutaneous coronary intervention randomized trial. *Circ Cardiovasc Interv*.2014;7(2):225-32.

